25O-NBOMe, also known as 2,4,5-TMPEA-NBOMe or as N-(2-methoxybenzyl)-2,4,5-trimethoxyphenethylamine, is a serotonin receptor modulator and putative psychedelic drug of the phenethylamine and 25-NB (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of 2C-O (2,4,5-trimethoxyphenethylamine).
The drug is known to act as a serotonin 5-HT2A receptor partial agonist, with an of 1.02 to 7.24nM and an of 57 to 129%. It activated the serotonin 5-HT2A receptor with 191- to 309-fold higher potency than 2C-O in vitro. 25O-NBOMe robustly and dose-dependently induces the head-twitch response, a behavioral proxy of psychedelic effects, in mice, with an of 0.70mg/kg. For comparison, in other studies in mice, the of 25I-NBOMe was 0.078mg/kg (9-fold lower) and of 25D-NBOMe was 0.23mg/kg (3-fold lower).
25O-NBOMe was first described in the scientific literature by 2009. It is a controlled substance in Canada under phenethylamine blanket-ban language.
See also 25-NB 25H-NBOMe TMA-2 2,4,6-TMPEA-NBOMe
References
External links 25O-NBOMe - Isomer Design